Cross-national drug price comparisons with economic weights in external reference pricing in Germany-Reference-Cited by-同舟云学术

Cross-national drug price comparisons with economic weights in external reference pricing in Germany

Published:2018-10-14 Issue:1 Volume:19 Page:37-43
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Mahlich Jörg¹²,Sindern Jörn¹,Suppliet Moritz³^ORCID

Affiliation:

1. Health Economics and Outcomes Research, Janssen-Cilag, Neuss, Germany

2. University of Düsseldorf, Institute for Competition Economics, Düsseldorf, Germany

3. TILEC and Department of Economics, Tilburg University, Tilburg, The Netherlands

Funder

Janssen-Cilag GmbH

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1527221

Reference55 articles.

1. The price of innovation: new estimates of drug development costs

2. Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU

3. Neubauer G, Morasch K, Gmeiner A Opportunities and benefits of price differentiation for innovative medicines. Study for the Association of Research-based Pharmaceutical Companies e.V. (VFA) 2013.

4. Post-TRIPS Options for Access to Patented Medicines in Developing Nations

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs);Research in Social and Administrative Pharmacy;2024-09

2. Editorial: Public Health Promotion and Medical Education Reform;Frontiers in Public Health;2022-05-04

3. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad;Research in Social and Administrative Pharmacy;2021-08

4. Determinants of drug prices: a systematic review of comparison studies;BMJ Open;2021-07

5. Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.;Frontiers in Pharmacology;2020-04-14